What bothers me are the facts that the shareholders were kept out in making a decision to sell stemcell assets to BioTime, no meeting lately with shareholders, no open-hearted company statement specifically addressed to shareholders, no response from Anna to shareholder's legitimate questions, much more friendlier attitude of Scarlett to his WS buddies than to shareholders, no reduction in his $2.3M total annual compensation despite reduced company size and the only product on hold for six months, and Huh as the COB. Hope everything works out well for us shareholders, specifically if Imetelstat is recognized and approved for FTD by the FDA. That's the only ray of light in our otherwise dark world of Geron.
He declared roughly two years ago that Imetelstat had "failed" for solid-tumor applications that caused a massive slide in the SP!!! He switched to hematological applications after that. How can he reverse himself now?!!
You forget that the PFS may be inadequate and those psychological long-term problems may be too severe for the survivors to experience that (if not "quick" but) "complete" recovery!!
I simply hope that the current management is not going to pass on whatever is left of this company to a large pharma of its choice, getting themselves some lucrative deals, and not much for shareholders. Yes, that will keep the science intact but at long-holding shareholders' cost!! To me, neither Scarlett nor Huh appears to be shareholder friendly. And, that concern of mine, in my view, is valid and legitimate, no matter what some dreamers project on this board.
I am lost!! Are they planning this combination to "this patient population" after having treated them with Imetelstat so far?!! If so, how would you measure the longer-term effect of treating with Imetelstat alone? Or is Imetelstat is not adequately effective and has no serious side effect so far?
Important thing to note is that Huh hasn't been able to keep his board membership long except at BiPar (i.e., the company he partly owned and sold to Sanofi) and at Geron. He has been at Geron board longest of all boards he had been!
Perhaps they have a need to watch for either side effects or effectiveness for a longer duration. You can make a better guess If you review results of the trial so far if those are published.
He still gets 2 up-thumbs and none down-thumb, indicating what kind of people visit this board!!! It's useless to give advice to or exchange views with idiots.
Let me repeat: the advice IS for investors, and not day traders!! So, traders, please do not wear the cap that doesn't fit you!!!!!
Thanks for some corrections, black_box, specifically, Bradbury purchase, $140M cash and not $100M, and "end of year submittal". Serious liver damage pertains to ET/PV, not MF!! The fact about short volume is important for traders, not so much for investors. If as you state, "everything works much better with Imetelstat", why is the FDA hold for Geron and partial to Mayo's work? Of course, Imetelstat didn't work for solid tumor and well for ET/PV!!
Well you get 17 up-thumbs and I get 6 down-thumbs!! That tells me pretty much, what kind of people visit this board!! Get my point , my dear: Go by facts, not by assumptions!! That's is the message!!
Should add some important facts to those stated above: Geron has no debt and is not burdened with preferred shares or such other commercial paper; Huh was brought to find partnership(s); Imetelstat was declared to have failed by Scarlett in solid-tumor trials in the past; since Scarlett joined, the company size has been shrunk substantially to save costs, and its stem-cell patents/rights have been sold to BioTime.
Go by facts and sensible logic, not based on assumptions. The facts are: The FDA complete hold for Geron is in place for six months, there is no news w.r.t. when the hold will be lifted; no news on Geron's submittal to he FDA and no date announced so far as to when that submittal will be; Geron has only one product, Imetelstat, now which HAS shown to get CRs and PRs to a significantly high percentage of advanced-stage MF patients; Imetelstat may be creating a serious liver issue if used alone for ET and PV; possibility exists for use of Imetelstat for other hematological applications; Geron has only $100M in cash and employs a staff of only 40 or so; Scarlett does get $2+M in annual compensation and Huh is currently the COB; there is no insider purchase of Geron shares since Scarlett's purchase last year; Geron doesn't have an officially announced board of expert consultants; Geron's multicenter Ph 2 MF trial may be directed by Tefferi as it is known to-day.
Use these facts and other facts, if I missed any, and make your own judgment without being influenced by either self-appointed pundits or bashers or pushers on this board or sources like Seeking Alpha.
America is going to loose as long the FDA has idiots or vested interests guiding it and the lobbies are effective. The lobbies are effective as long as each politician has to spend millions in getting elected, mostly to pay to media for advertising. It's our bloody system where money power wins politicians through the media. Nothing you or I can do about it!!!
Scis, where did you copy this info from? It apparently looks like from Geron. I haven't checked the Geron web site lately. In any case, there is needed cautiousness and it's wise to do so. But, possible expediency of actions also is needed from financial/commercial considerations. With only one drug in hand, adequate platform for its multiple applications is a wise approach instead of rushing prematurely for a partnership.